Clinigen and Amgen agree multi-product distribution deal

15 March 2021

UK-based Clinigen Group (AIM: CLIN) has signed a distribution agreement with Amgen (Nasdaq: AMGN) to supply part of its product portfolio to multiple countries across Africa and Asia.

Clinigen, a global pharmaceutical products and services company, has in recent years pursued a strategy of acquiring global rights to certain assets targeted for their potential to be renewed and have access broadened.

Under the terms of the distribution agreement, Clinigen will provide healthcare professionals in certain territories with access to medicines which are not currently on the market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK